Dermata Therapeutics, Inc. - DRMA STOCK NEWS

Dermata Therapeutics (NASDAQ: DRMA; DRMAW) reported significant updates in its clinical trials and financial performance for FY 2021. The DMT310 Phase 2 trial for rosacea is over two-thirds enrolled, with topline results expected in H2 2022, while a Phase 2 trial for psoriasis is anticipated to start in H1 2022. The company ended 2021 with $10.8 million in cash, up from $0.5 million in 2020. R&D expenses rose to $3.5 million from $1.6 million, and general administrative expenses increased to $4.4 million from $1.6 million. Dermata aims for an End of Phase 2 meeting with the FDA in Q1 2023.

Dermata Therapeutics (NASDAQ:DRMA), a clinical-stage biotechnology company, will participate in the 2022 Maxim Group Virtual Growth Conference from March 28-30, 2022. CEO Gerry Proehl is set to present a fireside chat on March 28 at 12:00 p.m. PT. Dermata specializes in treating medical and aesthetic skin conditions, with its lead product candidate, DMT310, targeting acne, psoriasis, and rosacea. The conference will be hosted live on M-Vest, allowing attendees to engage directly with company executives.

Dermata Therapeutics, Inc. (NASDAQ:DRMA) has appointed Brittany Bradrick to its Board of Directors and Audit Committee. Bradrick has over 25 years of experience in finance and corporate development in the life sciences sector. She has previously held senior roles at Neurelis and ViaCyte, and her expertise is expected to benefit Dermata's development of its product candidates, DMT310 and DMT410. This appointment follows Dr. Steven Mento's transition to a different committee role while remaining a director. Dermata focuses on treatments for medical and aesthetic skin conditions.

Dermata Therapeutics (NASDAQ:DRMA), a clinical-stage biotechnology company, announced that Gerry Proehl, its Chairman, President, and CEO, will present at the H.C. Wainwright BioConnect Conference from January 10-13, 2022. The presentation will be available on-demand starting January 10 at 7:00 a.m. ET. Dermata focuses on treating skin conditions with its lead product candidate, DMT310, aimed at acne, psoriasis, and rosacea. The company’s second candidate, DMT410, is designed for topical administration of botulinum toxin. A replay will be accessible on Dermata's website for 90 days.

Dermata Therapeutics announced positive efficacy and safety results from its Phase 1b proof of concept study evaluating DMT410, a topical treatment for aesthetic skin conditions. Key findings include observed improvements in pore size, luminosity, and overall skin brightness, lasting approximately 3 months. The study, involving 10 female patients, showed no adverse effects or distant spread of toxin. The company believes DMT410's delivery method expands market opportunities for botulinum toxins. Results were presented at The American Society for Dermatologic Surgery Annual Meeting.

Dermata Therapeutics (Nasdaq:DRMA) has enrolled its first patient in a Phase 2 trial for DMT310, aimed at treating moderate-to-severe rosacea, which affects approximately 16 million patients in the U.S. This trial, designed to evaluate the product's tolerability and efficacy over 12 weeks, anticipates topline results in the second half of 2022. DMT310 employs innovative Spongilla technology, targeting inflammatory pathways by inhibiting IL-17 production. If successful, it could redefine treatment options in dermatology, potentially becoming the first once-weekly topical solution for rosacea.

Dermata Therapeutics reported positive topline results from its DMT310 clinical trial for mild-to-moderate psoriasis, with 29.6% of patients achieving a PGA score of 0 or 1. The company successfully closed an upsized initial public offering (IPO) raising $18.0 million and appointed notable leaders to its Board and executive team. Dermata plans to present topline results from the DMT410 study on November 19, 2021, and initiate a Phase 2 study for DMT310 in rosacea in Q4 2021. As of September 30, 2021, Dermata had $12.6 million in cash, bolstered by its recent IPO.

Dermata Therapeutics (Nasdaq:DRMA) announced the presentation of efficacy and safety results for its Phase 1b proof of concept study evaluating DMT410 for treating multiple aesthetic skin conditions. The study, involving 10 patients, observed effects over 16 weeks and assessed various endpoints, including fine lines and luminosity improvements. Results will be presented by Dr. Rawaa Almukhtar at the ASDS Annual Meeting on November 19, 2021. DMT410 utilizes unique Spongilla technology for intradermal delivery of botulinum toxin.

Dermata Therapeutics (NASDAQ:DRMA) will host a virtual investor event on November 19, 2021, at 4:30 PM ET to present results of its DMT410 Phase 1b study targeting multiple aesthetic skin conditions. The event features presentations from Dr. Christopher Nardo and Gerry Proehl, focusing on the proof of concept evaluation initially shared at the American Society for Dermatologic Surgery meeting. DMT410 utilizes Dermata's Spongilla technology to deliver botulinum toxin topically and may offer a new treatment avenue for skin conditions.